Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Pfizer (NYSE:PFE) but lowered the price target from $35 to $34.
November 01, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Pfizer but lowered the price target from $35 to $34.
The lowering of the price target by Barclays indicates a potential decrease in Pfizer's stock value in the short term. This could lead to a negative impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100